50.08% of Global CAR-T Cell Therapy Treatment Market Revenue is generated by Yescarta Segment

 CAR T-cell therapy is a sort of T-cell therapy or treatment that fights cancer cells, with a market share of around 27% in the overall T-cell therapy market. The rising prevalence of cancer is likely to spur the development of CAR T-cells for therapeutic purposes. The potential for artificial T-cell receptors to be used to treat a wide range of malignancies has long been recognized. Chimeric immunoreceptors are becoming more popular because they help T-cells discover and kill cancer cells that carry the specific protein that the receptor can bind to.

Access Full Report @ https://www.databridgemarketresearch.com/es/reports/global-car-t-cell-therapy-treatment-market

Data Bridge Market Research analyses that the CAR-T cell therapy treatment market is expected to grow at a CAGR of 30.0% in the forecast period of 2021 to 2028 and is expected to reach USD 8,818.05 million by 2028. Growing focus on research and development therapies for cancer, such as colorectal cancer, multiple prostate cancer, lung cancer, and myeloma cancer, is anticipated to propel the CAR-T cell therapy treatment market's growth rate. Furthermore, favorable government policies for life science companies and surging demand for novel treatment options for cancer will enhance the market's growth rate.

Rising demand for biopharmaceuticals is expected to drive the market's growth rate during the forecast period 0f 2021-2028

As people become more aware of this novel way of treating cancer, demand for auto T cell therapy products rises. As a result, the industry's major players are working on new items, which is propelling the market forward. For instance, the US Food and Drug Administration authorized Yescarta, a cell-based gene therapy, in October 2017 to treat adult patients with certain kinds of large B-cell lymphoma. Yescarta's clearance is a breakthrough in the field of CAR-T cell treatments for cancer patients.

Report Scope and Market Segmentation

Segment Analysis:

The CAR-T cell therapy treatment market is segmented on the basis of product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel.

• On the basis of product, global CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells. In 2021, autologous CAR-T cells segment is expected to dominate the market with 100.00% market share because the drugs approved for CAR-T cell therapy are autologous in nature.
• On the basis of structure, global CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells. In 2021, second generation CAR-T cells segment is expected to dominate the market with 100.00% market share because the approved therapies are second generation based structure.
• On the basis of targeted antigens, global CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. In 2021, antigens on hematologic malignancies segment is expected to dominate the market with 100.00% market share because drugs approved for CAR-T cell therapy are majorly used for hematologic malignancies and ongoing extensive research development.
• On the basis of brand, global CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others. In 2021, yescarta segment is expected to dominate the market with 50.08% market share because yescarta is the first approved CAR-T cell therapy for oncology therapeutic class.
• On the basis of therapeutic application, global CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others. In 2021, follicular lymphoma segment is expected to dominate the market with 50.08% market share because yescarta accounts the major revenue in the market and the follicular lymphoma is the major indication for yescarta.
• On the basis of end user, global CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others. In 2021, hospitals segment is expected to dominate the market with 77.77% market share because CAR-T cell therapy required highly trained professionals with advanced technology laboratories.
• On the basis of distribution channel, global CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others. In 2021, hospitals pharmacy segment is expected to dominate the market with 77.77% market share because hospitals pharmacy are the central part of the hospitals, all the infusion related and medication related delivery sold by the pharmacy department.

Major Players

Data Bridge Market Research recognizes the following companies as the major Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Astellas Pharma Inc. (Japan), Bristol-Myers Squibb Company (U.S.), bluebird bio, Inc. (U.S.), Amgen Inc. (U.S.), Autolus (U.K.), Atara Biotherapeutics, Inc. (U.S.), Bellicum Pharmaceuticals, Inc. (U.S.).

Market Development

• In December 2020, Atara Biotherapeutics, Inc. announced their collaboration with Bayer AG to develop mesothelin-targeted CAR T-cell therapies for solid tumors. The main focus of company is on the development of ATA2271 for treating malignant pleural mesothelioma and non-small-cell lung cancer, as per the agreement. This collaboration accelerated the company's research and development for ATA2271 and allowed it to become the leading allogeneic CAR-T cell therapy manufacturer.
• In December 2021, Novartis announced the introduction of T-Charge. It is the company's next-generation CAR-T platform which will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. T cell stemness, or the ability to self-renew and mature, is preserved by the T-Charge platform, resulting in a product with increased proliferative potential and fewer tired T cells. T-Charge allows CAR-T cells to expand predominantly inside a patient's body (in-vivo), removing the requirement for an extensive culture time outside of the body (ex-vivo). These distinct features of the T-Charge platform could lead to greater and more long-lasting responses and a lower chance of severe side effects.

Regional Analysis

Geographically, the countries covered in the CAR-T cell therapy treatment market report are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa.

As per Data Bridge Market Research analysis:

North America is the dominant region in CAR-T cell therapy treatment market during the forecast period 2021 - 2028

North America will continue to dominate the CAR-T cell therapy treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the presence of major key players and the increasing number of research activities in this region. U.S. is estimated to dominate the North American region due to the increasing healthcare expenditure and well-established healthcare infrastructure for the autologous CAR-T cells segment.

Asia-Pacific is estimated to be the fastest growing region in CAR-T cell therapy treatment market the forecast period 2021 - 2028

Asia-Pacific region is anticipated to grow at the highest rate during the forecast period of 2021-2028 due to the growing government initiatives and rising healthcare expenditure in the region. Japan is leading the growth of the Asia-Pacific CAR-T cell therapy treatment market The autologous CAR-T cells segment is dominating in the country due to the increase in research regarding CAR-T cell therapy treatment.

COVID-19 Impact Analysis

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. The virus was rapidly spreading, so the authorities enforced a lockdown to stop it. The COVID-19 outbreak significantly impacted the world economy and all sectors. The worldwide pharmaceutical CAR-T cell therapy treatment industry, like other industries, was severely impacted by the COVID-19 pandemic. The abrupt enforcement of lockdown and social distance requirements disrupted the main pharmaceutical excipient firms' raw material delivery channel and supply chain. The lack of supplies has an impact on countries including China and India, resulting in a reduction in medication production all over the world. The pharmaceutical CAR-T cell therapy treatment sector benefited from the COVID-19 as well. Pharmaceutical CAR-T cell therapy treatment were utilized in R&D activities and it had a significant impact on several healthcare industries. However, it had a negative impact on pharmaceutical CAR-T cell therapy treatment in general.

For more detailed information about the CAR-T cell therapy treatment market report, click here –https://www.databridgemarketresearch.com/es/reports/global-car-t-cell-therapy-treatment-market